# Carnosine for Peripheral Vascular Disease

Study · id `cardio:ct-nct03844113` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03844113](<https://clinicaltrials.gov/study/NCT03844113>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03844113

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.

## Technical summary

Registry record NCT03844113. Randomized; quadruple masking; primary purpose treatment. Start 2019-03-01 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT03844113, source copy `cardio:ctgov-nct03844113-2020-12-29`, retrieved 2026-10-31)
- Started: 2019-03-01 (actual) (ClinicalTrials.gov record NCT03844113, source copy `cardio:ctgov-nct03844113-2020-12-29`, retrieved 2026-10-31)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT03844113, source copy `cardio:ctgov-nct03844113-2020-12-29`, retrieved 2026-10-31)
- Completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT03844113, source copy `cardio:ctgov-nct03844113-2020-12-29`, retrieved 2026-10-31)
- Countries: Australia (ClinicalTrials.gov record NCT03844113, source copy `cardio:ctgov-nct03844113-2020-12-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03844113-2020-12-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Carnosine for Peripheral Vascular Disease
- Acronym: Car-PVD
- Condition: Peripheral Arterial Disease
- Intervention (Drug): Carnosine
- Intervention (Drug): Placebo
- Lead sponsor: Monash University
- Lead sponsor class: OTHER
- Collaborator: Monash Health
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Monash University (`cardio:org-monash-university`)

## Provenance

Content hash: 353b4ac98ef2453f2e30fe0afce177a8fda1ee22aa2952f307152b5b4d25ecac
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
